Takeover offer to the shareholders of Epigenomics AG
Summit Hero Holding GmbH published further information about the offer on the website www.summit-hero-angebot.de. This includes the approved offer document, which was published on June 8, 2017.
We cannot assume any liability for the content and accuracy of the information provided.
+ + + Water mark report as of 22 June 2017: 26.09%* + + +
*Publication according to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) by Summit Hero Holding GmbH on 22 June 2017. As of June 22, 2017, 14:00 hrs (Frankfurt am Main local time) / 08:00 hrs (New York local time) the takeover offer has been accepted for a total of 11.79% of the share capital and the voting rights of Epigenomics AG. The total number of Epigenomics Shares for which the offer has been accepted until the notification date plus Epigenomics Shares directly held by persons acting jointly with the Bidder Epigenomics Shares subject to agreements entered into by the Bidder or by persons acting jointly with the Bidder under which the transfer of Epigenomics Shares may be demanded, and Epigenomics Shares underlying instruments pursuant to Section 25 para. 1 sentence 1 no. 2 WpHG corresponds to a proportionate participation of approximately 14.29% in the share capital. Epigenomics AG assumes no liability for the accuracy of the information provided.